Toll-like receptors (TLRs) constitute a family of nonpolymorphic receptors that are devoted to pathogen recognition. In this work, we have explored the impact of TLR ligands (TLR-L) on human hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). We show that HSCs and HPCs have a comparable pattern of expression of TLR transcripts characterized by the predominance of TLR1, -2, -3, -4 and -6. In longterm cultures of HSCs, HPCs and stromal cells, most TLR-L profoundly inhibited B-cell development while preserving or enhancing the production of myeloid cells. In short-term cultures, the TLR1/2 ligand PAM 3 CSK 4 induced a large proportion of HPCs to express markers of the myelomonocytic lineage. PAM 3 CSK 4 induced only marginal expression of myeloid lineage markers on HSCs but promoted their myeloid commitment as revealed by their acquisition of the phenotype of multi-and bipotential myeloid progenitors and by upregulation of the transcription factors PU.1, C/EBPa and GATA-1. Our results suggest that TLR agonists can bias the lineage commitment of human HSCs and shift the differentiation of lineage-committed progenitors to favor myelopoiesis at the expense of lymphoid B-cell development.
Introduction
The classical model of hematopoiesis proposes that pluripotent hematopoietic stem cells (HSCs) give rise to progenitors that have committed to either a lymphoid cell fate (common lymphoid progenitor; CLP) or a myeloid/erythroid cell fate (common myeloid progenitor; CMP). CLPs are believed to ultimately give rise to single-lineage progenitors committed to becoming T, B or natural killer (NK) cells. CMPs are postulated to generate two populations of bipotential progenitors: (1) the granulocyte/monocyte progenitor (GMP) and (2) the megakaryocyte/erythroid progenitor (MEP). 1 The establishment of all hematopoietic lineages during development is mediated by transcription factors that act in sequential and parallel fashions, building lineage-specific networks or circuits. 2, 3 There are two contrasting lines of thoughts regarding lineage commitment. The stochastic hypothesis implies that lineage choice is a cellintrinsic process that involves the stochastic upregulation of transcription factors or other regulatory molecules. The instructive hypothesis infers that hematopoietic cell fate is driven by extracellular factors including cytokines, direct cell-cell interactions or other environmental cues.
It has long been known that severe infections and inflammatory signals can affect the production of peripheral blood cells. Experimental pneumococcal infection accelerates the bone marrow release of neutrophils. 4, 5 Certain viruses, such as the Human Herpes virus-7 (HHV7), increase the maturation of human hematopoietic progenitor cells (HPCs) along the myeloid lineage. 6 Adjuvants and proinflammatory cytokines, such as tumor-necrosis factor-a and interleukin (IL)-1b, substantially reduce the numbers of lymphocytes in the bone marrow. 7, 8 More recently, the group of Kelsoe has documented that inflammatory signals, such as those provided by endotoxin, enhance granulopoiesis at the expense of lymphopoiesis in the mouse. 9, 10 It is now established that the immune system detects conserved microbial structures as danger signals. These pathogen-associated molecular patterns (PAMPs) provoke an immediate and robust immune response. Toll-like receptors (TLRs) belong to the pathogen recognition receptor (PRR) superfamily, which is devoted to the recognition of PAMPs. Nagai and colleagues have recently shown that TLR agonists promote the engagement of murine HSCs and early HPCs into the myeloid developmental path. 11 Two recent studies by Sioud et al. have documented that TLRs are also expressed on human cord blood CD34 þ cells and that TLR ligands (TLR-L) can favor their differentiation into mature functional myeloid cells belonging either to the monocytic or dendritic cell (DC) lineages. 12, 13 In this survey, we report that human HSCs and lineage-committed progenitors express a comparable TLR expression profile. In long-term cocultures of human HSCs and HPCs on the S17 stromal cell line, TLR agonists, such as the TLR1/2 ligand PAM 3 CSK 4 , profoundly inhibited B-cell development and promoted the emergence of myeloid cells. We show here for the first time that PAM 3 CSK 4 engages human HSCs to differentiate into CMPs and, to a lesser degree, into GMPs and MEPs. We bring evidence that the PAM 3 CSK 4 -induced priming of HSCs to the myeloid cell fate is correlated with the selective upregulation of a set of transcription factors known to promote myeloid commitment. Our results suggest that, in the course of microbial infection, TLR agonists can bias the developmental program of human HSCs and progenitors to increase the output of effector cells of the innate immune system.
Materials and methods

Antibodies and flow cytometry
The following antibodies were used for isolation of HSCs and HPCs from cord blood (CB) and for phenotypical studies. The lineage markers (Lin) cocktail was constituted of FITC-conjugated Abs to CD1a, CD7, CD14, CD16, CD19, CD41a, CD56, CD57, CD66b, CD116 (Becton Dickinson/BD Biosciences/Pharmingen, San Diego, CA, USA), CD8, CD11c, CD15, CD235a/glycophorin A (Dako, Glostrup, Denmark), CD3 (Immunotech, Marseille, France) and CD11b (Caltag/ Invitrogen, Cergy-Pontoise, France). For sorting of HSCs and HPCs, the Lin Ab cocktail was used in combination with the allophycocyanin (APC)-conjugated anti-CD34 and the phycoerythrin (PE)-Cy7-conjugated anti-CD38 mAbs (BD). The inclusion of an anti-CD7 mAb in the Lin cocktail ensured the depletion of multilymphoid progenitors (CLPs) defined in CB as CD34 þ CD38 À CD7 þ cells. 14 The anti-CD116 mAb was omitted from the Lin cocktail used for cell sorting because CD116 is expressed at variable degrees on myeloid progenitors. 15 The lymphoid-restricted Ab cocktail (Lin-L) was constituted of the anti-CD3, CD7, CD8, CD19, CD56 and CD57 mAbs. The macrophage/granulocyte/DC-restricted Ab cocktail (Lin-MGD) was constituted of the anti-CD1a, CD11b, CD11c, CD14, CD15, CD116 and CD66b mAbs. The megakaryocyte/erythrocyte-restricted cocktail was constituted of the anti-CD41a and anti-CD235a mAbs. The isotype-and fluorochrome-matched staining controls were purchased from the following sources: FITC-and APC-conjugated mouse immunoglobulin G1 (IgG1; Dako); PE-, PerCP-Cy5.5-and PE-Cy7-conjugated mouse IgG1 as well as FITC-conjugated mouse IgM (BD). Multiparameter flow cytometry analysis of committed myeloid progenitors (CMPs, GMPs and MEPs) was conducted with the following mAbs: FITC-conjugated Lin cocktail, APC-conjugated CD34 mAb (BD), PE-Cy7-conjugated anti-CD45RA mAb (BD), PEconjugated anti-IL3-Ra (CD123) mAb (BD/Pharmingen) and PerCP-Cy5.5-conjugated anti-CD38 mAb (BD/Pharmingen) as described elsewhere. 16 Appropriate isotype-matched, irrelevant control mAbs were used to determine the level of background staining and to set the staining thresholds for each fluorochrome. PE-conjugated Rat mAbs directed against mouse Gr1, CD11b, F4/80, CD93 and CD19 were purchased from BD/Pharmingen. Flow cytometry analyses were conducted either on a CANTO or on a FACScan analyzer (BD, Mountain View, CA, USA). HSCs and progenitors were sorted on a FACSVantage sorter (BD).
Reagents
The source and working concentrations of TLR-L are as follows: PAM 3 CSK 4 (10 mg/ml; Bachem, Voisins-Le-Bretonneux, France); poly:IC (100 mg/ml), lipopolysaccharide (LPS) (1 mg/ml), R848 (1 mM) and flagellin (1 mg/ml; InvivoGen, San Diego, CA, USA); MALP-2 (100 ng/ml; Alexis Biochemicals, Laufelfingen, Switzerland); CpG 2006 (50 nM; MWG Biotech AG, Ebersberg, Germany). The optimal concentration for each TLR agonist was defined as the concentration inducing the maximal 3 H-thymidine incorporation in mixed HSC and HPC (Lin À CD34 þ ) cultures conducted for 2 days.
Cell preparation
Umbilical CB samples were obtained from normal full-term deliveries following informed consent from the mothers and with approval of the Ethics Committee of the hospital. 
In vivo experiments
Twelve-week-old C57BL/6J mice were purchased from Charles River Laboratories (L'Arbresle, France) and maintained in pathogen-free conditions at the PBES (Ecole Normale Supérieure de Lyon, France). Rag2/gc double knockout (KO) mice on the BALB/c background were kindly provided by Dr M Ito (Central Institute for Experimental Animals, Kawasaki, Japan). 'Humanized' mice were generated as described earlier. 20, 21 Two-dayold Rag2/gc double KO mice were sublethally irradiated and subsequently reconstituted by intraperitoneal injection of 3 to 4 Â 10 5 CD34 þ cells sorted from human cord blood. At 8 weeks of age, the human hematopoietic cell engraftment, as estimated by the proportions of CD45 þ cells, was 50±18% in the bone marrow and 29 ± 12% in the spleens (means ± s.d. values from nine engrafted mice). Humanized Rag2/gc double KO (8 weeks after reconstitution) and C57BL/6 mice were injected IP with phosphate-buffered saline (PBS) or PAM 3 CSK 4 (25 mg). Mice were killed 3 days after injection and expression of different lymphoid and myeloid markers was analyzed in the bone marrow and in the spleen.
Statistical analysis
Statistical significance of differences was determined by the paired two-tailed Student's t-test using the GraphPad software version 4.0. Differences were considered statistically significant for P values o0.05 (*), o0.01 (**), o0.001 (***).
Results
Human HSCs and HPCs express functional TLRs
The pattern of expression of the 10 human TLR transcripts and of the two main TLR adaptors (MyD88 and TRIF) was analyzed by real-time RT-PCR in human HSCs and HPCs sorted from CB as Lin À CD34 þ CD38 lo and Lin À CD34 þ CD38 hi cells, respectively. The postsort purity of both populations was superior to 97%. As shown in Figure 1a , HSCs and HPCs displayed a comparable TLR profile characterized by the prominent expression of the TLR1, -3 and -6 transcripts, the marginal expression of TLR2 and -4 and the low (TLR5, -7, -8, -9, -10) expression of the other TLR mRNAs. The patterns of expression of MyD88 and TRIF were comparable in both populations (Figure 1b) . To test the functionality of the TLRs expressed by HSCs and progenitors, we first estimated the impact of various TLR-L on the proliferation of a mixed population of HSCs and HPCs (Lin À CD34 þ cells). As shown in Figure 1c , with the exception of flagellin (TLR5 ligand), all TLR agonists tested the stimulated proliferation of Lin À CD34 þ cells to variable degrees but PAM 3 CSK 4 (ligand of the TLR1/2 heterodimer) was consistently the most potent growth stimulator. We next compared the susceptibility of HSCs and HPCs with the growth-stimulatory effect of PAM 3 CSK 4 . As illustrated by Figure 1d , PAM 3 CSK 4 stimulated the proliferation of both cell types but the amplitude of the response was higher in progenitors than in HSCs. We next monitored the contribution of endogenously produced cytokines to the growth-promoting effect of PAM 3 CSK 4 . We focused on six hematopoietic factors (IL-3, M-CSF, SCF, GM-CSF, G-CSF and FLT3-L) known to promote expansion and/or differentiation of HSCs and/or HPCs. Two of them (G-CSF and GM-CSF) were produced at detectable levels by PAM 3 CSK 4 -stimulated Lin À CD34 þ cells (Supplementary Figure 1) but neutralizing anti-G-CSF and anti-GM-CSF Abs failed to inhibit the stimulatory effect of PAM 3 CSK 4 on the proliferation of these cells (data not shown). Altogether, these observations indicate that human HSCs and HPCs express functional TLRs that can transduce growth-stimulatory signals to these cells.
TLR agonists repress human B-cell lymphopoiesis
To examine the influence of TLR-L on the hematopoietic potential of HSCs and progenitors, we first used long-term cultures of CB Lin À CD34 þ cells seeded on the S17 murine bone marrow stromal cell line. This culture system has previously been described to support differentiation of HSCs along the B-lineage pathway. 17, 18 Cultures were pursued on S17 for 2 weeks without exogenous cytokines, in the presence or absence of various TLR-L (added twice at days 0 and 7). At the end of the cultures, emerging hematopoietic cells were analyzed by flow cytometry for the expression of a series of lymphoid and myeloid markers. Figure 2a illustrates the outcome of PAM 3 CSK 4 stimulation on the expression of: (1) the pan-B marker CD19 and the pan-myeloid marker CD33, (ii) the macrophage/ granulocyte/DC lineage markers CD11b, CD11c, CD14 and CD116 (GM-CSF-R). As expected, CD19 þ B cells were more represented than CD33 þ myeloid cells in control cultures. Accordingly, expression of the above-mentioned myeloid markers was marginal in cultures conducted without PAM 3 CSK 4 . By contrast, PAM 3 CSK 4 -stimulated cultures were characterized by a drastic reduction of the percentage of CD19-expressing cells and by a significant rise in the proportion of cells (40% on average) that express the myeloid markers CD33, CD11b, CD11c, CD14 and CD116. The T-cell (CD3) and NKcell (CD16, CD56) markers as well as the other myeloid markers examined (CD114, CD115, CD66b, CD235a and CD41a) remained virtually undetectable, irrespective of the culture conditions applied (data not shown). We conclude that PAM 3 CSK 4 induces emergence of myeloid cells that bear macrophage/granulocyte/DC markers but does not promote differentiation of cells belonging to the T, NK, megakaryocytic or erythroid lineages. The absolute numbers of myeloid and B cells were also estimated in cultures supplemented or not supplemented with various TLR agonists. As shown in Figure 2b , the modifications of the staining profiles in PAM 3 CSK 4 -stimulated cultures truly reflect a reduction in the B-cell (CD19 þ ) numbers and a concomitant rise in the myeloid cell (CD33 þ ) numbers produced. Furthermore, all TLR agonists did not display comparable effects on B-cell lymphopoiesis and myelopoiesis in the S17 culture model. CpG oligonucleotides (TLR9), LPS (TLR4) and poly:IC (TLR3) reduced B-cell lymphopoiesis but failed to significantly enhance myelopoiesis. Flagellin did not inhibit the B-cell output but slightly enhanced myelopoiesis, whereas only PAM 3 CSK 4 (TLR1/2) and, to a lesser degree, R848 (TLR7 and 8) repressed B-cell lymphopoiesis and enhanced myelopoiesis. Therefore, these results emphasize that PAM 3 CSK 4 is not only the most potent stimulator of the proliferation and myeloid differentiation of Lin À CD34 þ cells but also the most efficient repressor of their B-cell differentiation. It was thus chosen to explore further the modulatory functions of TLR agonists on the hematopoietic potential of human HSCs and HPCs. Altogether, these observations show that most TLR agonists repress B-cell lymphopoiesis in long-term cultures of CB Lin À CD34 þ on S17 cells and that some of them (including PAM 3 CSK 4 ) shift the cell output of this culture system from B cells to myeloid cells.
PAM 3 CSK 4 promotes the differentiation of isolated HPCs along the myeloid pathway
To explore whether the triggering of TLR 1/2 on HSCs and HPCs affected their differentiation capacities, both cell types were isolated from CB and cultured for 6 days with or without PAM 3 CSK 4 in the absence of stromal cells. The resulting cell populations were stained with four different Ab cocktails identifying the markers distributed on mature hematopoietic cells belonging either to the lymphoid or the myeloid lineages. The expression of CD38 was also monitored as a means to globally estimate the proportions of early HPCs. As shown in Figure 3a , unstimulated cultures of HSCs contained only few viable cells, as estimated by the FSC/SSC gate, whereas unstimulated cultures of HPCs were more viable. Both HSCs and HPCs underwent important morphological changes when they were exposed to PAM 3 CSK 4 as revealed by the emergence of a population of cells with a high side scatter value. Following PAM 3 CSK 4 stimulation, CD38 was upregulated on more than 90% of the cells in HSC cultures, whereas the expression of this marker was not significantly induced in unstimulated cultures. CD38 expression remained high in progenitor cultures, irrespective of the addition of PAM 3 À CD34 þ cells were seeded on a confluent monolayer of S17 cells and cultured in the presence or absence of an optimal concentration of PAM 3 CSK 4 . Cells were collected 2 weeks after initiation of the cultures and stained with the indicated phycoerythrin (PE)-conjugated Abs. On account of the heterogeneity in size and granulometry of the cells that emerged from the S17 cultures, we chose to show dot plots that combine the fluorescence and side scatter (SSC) parameters. The forward/side light scatters were used to gate out dead cells and S17 stromal cells. The staining performed with the unrelated isotype-and fluorochrome-matched (IgG1) control Ab (ctrl) was used to define the fluorescence analysis gate for the markers. 
To better define the myeloid cell types that were produced from HSCs and progenitor cultures on PAM 3 CSK 4 stimulation, cells were next stained separately with each one of the Abs that constitute the Lin-MGD and the Lin-ME Abs cocktails. As illustrated by Figure 4a , PAM 3 CSK 4 -stimulated HSC cultures contained equivalent numbers of CD11b þ , CD11c þ , CD15 þ and CD41a þ cells. Cells expressing the monocyte marker CD14, the GM-CSF-R (CD116) or the DC/Langerhans cell marker CD1a were also found but at lower frequencies. In PAM 3 CSK 4 -stimulated HPC cultures, the numbers of CD11b þ , CD11c þ and CD15 þ cells were roughly equivalent to the overall numbers of Lin þ cells (Figure 4b ), thus suggesting that CD11b, CD11c and CD15 must be largely coexpressed. The size of the CD14-or CD116-expressing populations represented approximately two-third of that of the Lin þ compartment, whereas CD1a-expressing DCs were approximately four times less represented than Lin þ cells. The numbers of CD66b þ granulocytes were marginal. In contrast with HSC cultures, the population that emerged from PAM 3 CSK 4 -stimulated HPC cultures lacked expression of the megakaryocytic marker CD41a. CD11b expression was consistently found as one of the phenotypical hallmarks of the populations emerging from HSC or HPC cultures conducted with PAM 3 CSK 4 . As this marker can be expressed on different myeloid lineages, double stainings were next performed by combining the CD11b mAb with Abs directed against markers that identify more specifically DCs (CD1a), monocytes/macrophages (CD14) or granulocytes (CD15). CD1a-expressing cells constituted only a minor fraction of the CD11b þ population (15% on average) originating from PAM 3 CSK 4 -stimulated cultures of HPCs. By contrast, CD15 þ and CD14 þ cells both constituted approximately 60% of the CD11b þ population in these cultures, suggesting a significant level of coexpression of these two markers. Some CD11b À CD15 þ cells were also generated, but, owing to the weak expression of CD66b in these cultures, these cells are unlikely to be fully mature granulocytes. They could represent myeloid differentiation intermediates such as myelocytes or promyelocytes. These findings suggest that the stimulation of HPCs with PAM 3 CSK 4 preferentially promotes the generation of monocyte/macrophages coexpressing CD14 and CD15 and marginally gives rise to DCs. This conclusion was further supported by examination of the morphology of the cells at the end of the culture (Figures 4e and f) 
PAM 3 CSK 4 shifts the transcriptional network of HSCs toward the myeloid path
Transcription factors are instrumental in the development of hematopoietic lineages because they establish gene expression programs that dictate lineage choice. 1 Hence, they are expected to be expressed at higher levels in lineage-committed cells than in HSCs. To determine the impact of PAM 3 CSK 4 on the transcriptional network of HSCs, RNA extracts were prepared from freshly isolated HSCs or HPCs and from HSCs after a 6-day culture with PAM 3 CSK 4 . They were then processed for quantification of GATA-1, PU.1, C/EBPa and Pax5 transcripts by real-time RT-PCR. PU.1 governs B cell as well as macrophage and myeloid DC development. 22 Low levels of PU.1 are compatible with a B-cell fate, whereas high PU.1 levels specify the macrophage lineage. 23 Pax5 is required for B-cell commitment and differentiation. 24 GATA-1 is a dominant factor for erythroid/megakaryocyte/ eosinophil differentiation. 25, 26 C/EBPa is a key player in the regulation of granulopoiesis, 27, 28 and is also required for the transition from CMPs to GMPs in the mouse. 29 Enforced expression of C/EBPa also induces the reprogramming of B and T cells into macrophages. 30, 31 As shown in Figures 5a and b Figure 5a ) and also enhanced on average 3-fold the relative expression of the PU.1 transcript in HSCs (Figure 5b ). It is noteworthy that expression of these transcripts in PAM 3 CSK 4 -stimulated HSCs reached levels that were either equivalent to (C/EBPaPU) or comparable with (GATA-1) their levels of constitutive expression in freshly isolated HPCs. By contrast, PAM 3 CSK 4 only marginally modulated the expression of the Pax5 transcripts in HSCs (Figure 5b ). Altogether, these observations suggest that engagement of the TLR1/2 heterodimer induces modifications of the transcriptional balance of HSCs that are consistent with their commitment to the myeloid lineage.
PAM 3 CSK 4 promotes the differentiation of HSCs into early myeloid progenitors
In humans, CD38 is an early indicator of multilineage commitment 32 and it is distributed on CMPs, GMPs and MEPs. 15, 16 Our observation that PAM 3 CSK 4 induced CD38 expression on most HSCs thus raised the possibility that this TLR-L could induce HSCs to differentiate into myeloid progenitors. To check this hypothesis, we relied on the previously documented phenotypic definition of human pluripotential and bipotential myeloid progenitors. 15, 16 CMPs are defined as Lin
We used multiparameter flow cytometry to compare the expression of these markers on freshly isolated HPCs and on HSCs after a 6-day culture with PAM 3 CSK 4 . This analysis was not conducted on HSCs cultured for 6 days in the absence of stimuli because of the poor cell viability of unstimulated HSC cultures. As expected, HPCs sorted as Lin À CD34 þ CD38 hi could be further separated into three populations that fitted with the phenotypic definition of CMPs, GMPs and MEPs, based on the expression of CD45RA and IL3Ra (Figure 6 ). A minor fourth population defined as CD45RA þ /IL3Ra hi was also identified. As found earlier, PAM 3 CSK 4 induced expression of lineage (Lin) markers on a minority of HSCs that were gated out. It also upregulated CD38 on most cells but with a heterogeneous density of expression, thus leading us to gate CD38 hi cells. Examination of the CD45RA and IL3Ra stainings in this analysis window revealed a pattern of expression of these markers that was similar to that observed for freshly isolated HPCs. CMP, GMP and MEP subsets were identified in proportions that were comparable to those found in HPCs, that is, predominance of CMPs and a lesser representation of GMPs and MEPs. These findings thus support the notion that PAM 3 CSK 4 instructs human HSCs to undergo a commitment step to the myeloid lineage by promoting their differentiation into CMPs and, to a lesser extent, into GMPs and MEPs. (25 mg/mouse) or LPS (100 mg/mouse), administered 3 days before analysis of the spleen and bone marrow hematopoietic compartments, was tested by monitoring expression of the following markers: Gr1, CD11b, F4/80 (for the myeloid populations); CD19 used in combination with AA4.1 (for B cells). Both PAM 3 CSK 4 and LPS treatments induced a decrease (approximately by half) in the proportions of B cells in the bone marrow ( Figure 7a ) and a corresponding increase in the proportions of macrophages (F4/80 þ , CD11b þ ) and granulocytes (Gr1 þ ). The most drastic depletion in the bone marrow was observed for the pre-pro-B cell (CD19 þ /AA4.1 þ ) compartment, which was reduced to one-fifth of its size in LPStreated mice (data not shown). The splenic B-cell compartment (Figure 7b ) was only marginally affected by administration of TLR agonists, but both PAM 3 CSK 4 and LPS induced a significant rise in the proportions of splenic macrophages. Although PAM 3 CSK 4 and LPS promoted a comparable contraction of the B-cell compartment in the bone marrow, LPS was more efficient than PAM 3 CSK 4 in stimulating the production of macrophages in the bone marrow and spleen.
To explore the impact of PAM 3 CSK 4 on human myeloid cell differentiation in vivo, we used 'humanized' Rag2/gc double KO mice reconstituted with human CD34 þ cells sorted from human cord blood. The protocol of TLR agonist administration defined earlier for C57BL/6 mice was applied to humanized mice. At 8 weeks of age, three mice received a single IP injection of PBS and six mice received a single IP injection of PAM 3 CSK 4 (25 mg/mouse). Bone marrows and spleens were collected 3 days after injection. Human hematopoietic cells were gated by staining with an anti-CD45 mAb and analyzed by flow cytometry for the expression of:
(1) the B-cell marker CD19; (2) the macrophage and DC markers CD14, CD11b, CD11c; (3) the macrophage/granulocyte/DC markers, lymphoid markers and megakaryocyte/erythrocyte markers using the appropriate Lin-MGD, Lin-L and Lin-ME Ab cocktails, respectively. As illustrated in Figures 7c and d , PAM 3 CSK 4 injection failed to modulate expression of any of these markers either in the spleen or in the bone marrow. Thus, although PAM 3 CSK 4 can bias hematopoietic development in favor of myeloid lineage in C57BL/6 mice in vivo, it fails to do so in Rag2/gc double KO mice engrafted with human HSCs and HPCs.
Discussion
In this work, we show that TLR agonists can bias human hematopoiesis in favor of myeloid development by targeting TLR agonists drive the myeloid commitment of HSCs K De Luca et al both HSCs and HPCs. The novel finding that emerged from our study is that TLR-L such as PAM 3 CSK 4 not only favor the development of macrophages from HPCs but also exert a lineage-instructive function by engaging HSCs along the myeloid path. This assertion is substantiated by our finding that the PAM 3 CSK 4 stimulation of HSCs selectively enhances expression of GATA-1 and C/EBPa, two transcription factors associated with commitment to the megakaryocyte/erythroid and granulocyte lineages, respectively. This observation does not necessarily mean that the genetic program of the descendent cells has been fixed to either one or the other of these lineages, but rather reflects the differentiation of HSCs into bi-and multipotential myeloid progenitors that are known to coexpress different lineage-determining transcription factors at low levels. 15 This hypothesis is coherent with the results of the five-color immunofluorescence analysis that revealed that the progeny of PAM 3 CSK 4 -stimulated HSCs mostly bears the phenotypical attributes of CMPs. Nonetheless, the weak upregulation of PU.1 in HSCs in response to PAM 3 CSK 4 is puzzling because this transcription factor is required to generate CMPs from stem cells 33 and is expected to be expressed in CMPs and GMPs. 1, 15 However, only slight changes of the expression of PU.1 were reported for murine HSCs stimulated by TLRs, despite their massive differentiation into macrophages. 11 The possibility that low levels of endogenous PU.1 in HSCs may allow activation of the myelomonocytic program when C/EBPa is in excess is worth considering, because the enforced expression of C/EBPa is sufficient to reprogram mouse B cells to become macrophages. 30 There is evidence that adjacent cells and local cytokines contribute to the decision of stem cells to differentiate rather than to undergo self-renewal. 34 Our present data suggest that extrinsic microbial stimuli are also able to push HSCs to undergo differentiating divisions.
The pattern of TLR expression that we report for CB HSCs and HPCs is different from that reported by Sioud et al. 12 for human bone marrow CD34 þ cells. The TLR4, -7 and -8 transcripts that were found to be prominent in the aforementioned study are only marginally expressed by CB HSCs and HPCs. The different sources of hematopoietic cells (adult in the Sioud's study versus neonatal in this work) are likely to contribute to this discrepancy inasmuch as it has been documented earlier that primitive HSCs from CB have a distinct gene expression profile from their counterparts in adult bone marrow. 35 PAM 3 CSK 4 failed to promote differentiation of most HSCs beyond the multi-or bipotential myeloid progenitor stage, whereas it induced emergence of fully differentiated myeloid cells from HPCs. We cannot exclude the possibility that the differential outcome of PAM 3 CSK 4 stimulation on the differentiation of HSCs and HPCs may be imputable to the relatively short-term culture period (6 days), possibly insufficient to allow differentiation of HSCs into mature myeloid cells. In our study, the differentiated cells that emerged from cultures of HPCs or HSCs conducted with PAM 3 CSK 4 belonged in their great majority to the monocyte/ macrophage lineage. This observation is in contrast with the results of Sioud et al. showing that human bone marrow progenitors cultured under the same stimulatory conditions produce CD1a þ Langerhans-type DCs. 13 The rewiring of the TLR1/2 signaling pathways to distinct hematopoietic differentia- tion programs in CB and bone marrow progenitors cannot be excluded but seems unlikely. We rather favor the hypothesis that these differences pertain to the differential cellular composition of the two progenitor populations. Beyond this issue lies the question of how TLR-L modulate the cell fate of HPCs. We envisage three mechanisms that are not mutually exclusive. The first possibility is that TLR agonists behave as surrogate hematopoietic growth factors. We observed that a significant fraction of HPCs (Figure 3 ) spontaneously differentiates into mature cells bearing monocyte/macrophage markers in vitro. We show here that most TLR-L are potent growth stimulators for human HPCs. Hence, they could expand a population of myeloid progenitors that has been committed in vivo to the macrophage cell fate. The second possibility is that HPCs (but not HSCs) could produce cytokines that can complement TLR signaling to promote terminal myeloid maturation in response to TLR stimulation. This hypothesis is coherent with our present results (Supplementary Figure 1) and with the recent demonstration that TLR agonists induce the production by human CD34 þ progenitors of several cytokines including hematopoietic growth factors such as GM-CSF and GCSF. 13 Nevertheless, the contribution of autocrine cytokines to the TLR-mediated myeloid differentiation of HPCs remains unclear, as blocking Abs directed against GM-CSF or the M-CSF receptor failed to repress the TLR-L-induced macrophage differentiation from murine myeloid progenitors. 11 It is noteworthy that in our hands such blocking Abs also failed to repress the TLR-L-induced proliferation of human CD34 þ progenitors. The third possibility is that TLR agonists are able to trigger a shift in the transcriptional network of HPCs as they do for HSCs. The validity of this hypothesis has been formally shown for murine lymphoid progenitors, which can be reprogrammed by TLR-L for the production of DCs in single cell cultures. 11 TLR agonists have been described to stimulate the myeloid differentiation pathway of murine HSCs and progenitors at the expense of B-cell lymphopoiesis. 11 In agreement with these findings, we found that most TLR agonists were able to profoundly repress B-cell lymphopoiesis in long-term cultures conducted on S17. It is reasonable to speculate that extinction of the B-lymphoid program by PAM 3 CSK 4 is linked to the establishment of a transcription factor network that, in addition to promoting the myeloid cell fate, knocks down lymphoid transcription factors. Several hematopoiesis transcriptional regulators physically interact and interfere with each other's transcriptional function. CEBP/ a, for example, which is strongly upregulated by PAM 3 CSK 4 in HSCs, is known to inhibit the activity of Pax5 on the CD19 promoter. 30 This explanation cannot be invoked for the TLR9 and TLR4 ligands that both strongly suppress B-cell lymphopoiesis despite the fact that they exert no stimulatory effect on myelopoiesis in the S17 culture model. The impact of TLR agonists on myelopoiesis is neither linked to the selective usage of the MyD88 or TRIF pathways. PAM 3 CSK 4 and CpG oligonucleotides (TLR9 ligand) both recruit MyD88 but only the former TLR agonist significantly enhanced myelopoiesis. Furthermore, the TLR3 ligand, which exclusively recruits TRIF, hardly modulates myelopoiesis. The contribution of stromal cells cannot be excluded because they also express TLRs and might produce hematopoietic regulatory factors on TLR stimulation. Finally, the differential distribution of TLRs on discrete HPC populations (CMPs and GMPs, for instance) that have not been resolved in this study may also weigh on the biological response induced by a given TLR agonist in a mixed HPC and HSC population. Future experiments will have to address these questions.
We also show here that injection of PAM 3 CSK 4 into C57BL/6 mice represses the global B-cell output of the bone marrow and enhances the production of granulocytes and macrophages. This finding extends the observation of Nagai and colleagues 11 showing the in vivo modulatory effect of LPS on hematopoiesis. It suggests that the capacity to enhance myelopoiesis at the expense of B-cell development in vivo is not restricted to a single TLR agonist. The lack of modulatory effect of PAM 3 CSK 4 on human hematopoiesis in 'humanized' mice is thus unlikely to relate to a failure of PAM 3 CSK 4 to diffuse in the bone marrow or to an inappropriate protocol of administration of this TLR agonist in mice. We favor the explanation that the resistance of human HSCs and HPCs to the effects of TLR agonists 'in vivo' relates to their strong bias in favor of the production of B lymphocytes when they are engrafted in Rag2/gc double KO mice. Indeed, CD19 þ B cells constitute on average 20% of the hematopoietic compartment in mouse bone marrow, whereas they represent 61±6% of the human hematopoietic cells in the bone marrow of 'humanized' mice (Figures 7a and c) . This dominance of B cells among the hematopoietic populations that develop in humanized Rag2/gc double KO mice is not a singularity of our experiments inasmuch as it was also pointed out in the pioneering studies conducted by the group of H Spits with these mice. 21 We have documented in this paper that TLR agonists exert at least part of their stimulatory effect on myelopoiesis by modifying the transcriptional network of HSCs. It may be envisaged that this transcriptional program is more strongly 'locked' and less susceptible to modulation by environmental cues when HSCs are transplanted in irradiated immunodeficient mice. This could pertain to the respective basal levels of expression of myeloid and lymphoid transcription factors in HSCs and HPCs facing the active regeneration of a hematopoietic system after emptying of the hematological niches. In other words, we postulate that human hematopoiesis in such mice differs from hematopoiesis under normal steadystate conditions. The fact that it is poised toward B-cell production may counteract the myeloid differentiation shift promoted by TLR agonists.
In conclusion, our present work, together with data published earlier, [11] [12] [13] suggests that the hematopoietic system globally responds to pathogen infection by enhancing the production of cells (macrophages, DCs and granulocytes) that belong to the innate arm of the immune system. By ensuring the handling and presentation of microbial Ag as well as the destruction of the whole microorganisms, they are capable of dealing efficiently and rapidly with the infection. This phenomenon is at least partially mediated by TLRs and requires the coordinated response of different actors of hematopoiesis. First, as shown by the group of Kelsoe, TLR signals act on stromal cells by repressing the production of factors such as CXCL12 that are involved in the growth and retention of B-cell progenitors. 9, 10 They favor the egress of lymphocytes out of the bone marrow, thus liberating space for the granulocyte progenitors that share the same developmental niche. Second, TLR signals exert a permissive function on HPCs by promoting their outgrowth and terminal maturation into myeloid cells of the monocyte/ granulocyte/DC lineages. Third, as we show here, TLR signals also act at a very early developmental stage by enhancing the myeloid gene expression program of HSCs, thereby promoting their differentiation into myeloid progenitors.
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